Researchers at Mayo Clinic are studying new ways to diagnose and treat cholangiocarcinoma. This research is conducted as part of the Gastrointestinal Cancer Program and in coordination with the Mayo Clinic Cancer Center.
The Mayo Clinic Cancer Center receives funding from the National Cancer Institute (NCI) and is an NCI-designated comprehensive cancer center — recognition for an institution's scientific excellence and multidisciplinary resources focused on cancer prevention, diagnosis and treatment.
Areas of research include:
- Discovering that aspirin use may help prevent bile duct cancer
- Studying the molecular genetics of a tumor and identifying biomarkers, which may aid in early diagnosis or lead to new targeted therapies
- Doing clinical trials for new targeted therapies, which is possible because of Mayo Clinic's high patient volume for primary sclerosing cholangitis and bile duct cancer
- Improving safety of procedures and developing new ones
- Proving that a biomarker called CA 19-9 is useful in staging a tumor
See a list of publications on cholangiocarcinoma by Mayo Clinic doctors on PubMed, a service of the National Library of Medicine.